Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A119KH | ISIN: IL0011319527 | Ticker-Symbol: 1BT
Frankfurt
27.06.25 | 08:00
1,020 Euro
-3,77 % -0,040
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ENLIVEX THERAPEUTICS LTD Chart 1 Jahr
5-Tage-Chart
ENLIVEX THERAPEUTICS LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,0401,05014:46
1,0201,05014:45

Aktuelle News zur ENLIVEX THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.06.RedChip Companies, Inc.: Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV273ORLANDO, FL / ACCESS Newswire / June 13, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics (NASDAQ:ENLV) and Foremost Clean Energy (Nasdaq:FMST) on the RedChip Small Stocks, Big...
► Artikel lesen
10.06.Enlivex Therapeutics Ltd: Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology9
30.05.Enlivex Therapeutics Ltd. - 6-K, Report of foreign issuer3
30.04.Enlivex Therapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers5
24.04.Enlivex stock holds Buy rating with $7 target from H.C. Wainwright13
ENLIVEX THERAPEUTICS Aktie jetzt für 0€ handeln
21.04.Enlivex Therapeutics Ltd: Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis214Nes-Ziona, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
► Artikel lesen
21.04.Enlivex Therapeutics Ltd. - 6-K, Report of foreign issuer1
03.04.Enlivex Therapeutics Ltd: Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis141Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to 12% of the population globallyTMJ...
► Artikel lesen
03.04.Enlivex Therapeutics Ltd. - 6-K, Report of foreign issuer1
24.03.Enlivex stock price target raised to $7 at H.C. Wainwright1
17.03.Enlivex Therapeutics Ltd: Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis2
17.03.Enlivex Therapeutics Ltd. - 6-K, Report of foreign issuer2
04.03.Enlivex Therapeutics Ltd: Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra Trial in Knee Osteoarthritis1
03.03.Enlivex Announces Positive Interim Data From Early Stage Trial For Osteoarthritis Treatment1
03.03.Enlivex Therapeutics Ltd: Enlivex Announces Positive Interim Data - Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis199Nes-Ziona, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive...
► Artikel lesen
03.03.Enlivex Therapeutics Ltd. - 6-K, Report of foreign issuer-
18.02.Enlivex Therapeutics Ltd: Enlivex Issues Urgent Statement on Fraudulent News Dissemination149Ness-Ziona, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq and TASE: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, alerts investors...
► Artikel lesen
18.02.Enlivex Therapeutics Ltd. - 6-K, Report of foreign issuer-
10.01.Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV375ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small...
► Artikel lesen
11.12.24Enlivex Therapeutics Ltd: Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis303Ness-Ziona, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
► Artikel lesen
Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1